Nasdaq:US$15.21 (-0.78) | HKEX:HK$24.65 (+0.95) | AIM:£2.44 (-0.04)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors